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Aims There is lack of conclusive evidence from randomized clinical trials on the efficacy and safety of upgrade to cardiac re-
synchronization therapy (CRT) in patients with implanted pacemakers (PM) or defibrillators (ICD) with reduced left
ventricular ejection fraction (LVEF) and chronic heart failure (HF). The BUDAPEST-CRT Upgrade Study was designed
to compare the efficacy and safety of CRT upgrade from conventional PM or ICD therapy in patients with intermittent
or permanent right ventricular (RV) septal/apical pacing, reduced LVEF, and symptomatic HF.
Methods
and results
The BUDAPEST-CRT study is a prospective, randomized, multicentre, investigator-sponsored clinical trial. A total of
360 subjects will be enrolled with LVEF ≤ 35%, NYHA functional classes II– IVa, paced QRS ≥ 150 ms, and a RV
pacing ≥ 20%. Patients will be followed for 12 months. Randomization is performed in a 3:2 ratio (CRT-D vs. ICD).
The primary composite endpoint is all-cause mortality, a first HF event, or less than 15% reduction in left ventricular
(LV) end-systolic volume at 12 months. Secondary endpoints are all-cause mortality, all-cause mortality or HF event,
and LV volume reduction at 12 months. Tertiary endpoints include changes in quality of life, NYHA functional class,
6 min walk test, natriuretic peptides, and safety outcomes.
Conclusion The results of our prospective, randomized, multicentre clinical trial will provide important information on the role of
cardiac resynchronization therapy with defibrillator (CRT-D) upgrade in patients with symptomatic HF, reduced LVEF,
and wide-paced QRS with intermittent or permanent RV pacing.
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Introduction
Cardiac resynchronization therapy (CRT) reduces morbidity and
mortality in selected patients with heart failure (HF) and broad
QRS complex (≥130 ms). Large randomized clinical trials have
shown improvement in cardiac function and decreased HF events
or all-cause mortality, mainly in patients with de novoCRT device im-
plantations.1–4 However, 28% of CRT implantations in Europe are
upgrade procedures after previously implanted cardiac devices.5 To
date, there are no conclusive data on the superiority of cardiac re-
synchronization therapy with defibrillator (CRT-D) over implanta-
ble cardioverter defibrillator (ICD) in patients with previously
implanted pacemaker (PM) or ICD devices with reduced left ven-
tricular (LV) function and symptomatic HF who require intermittent
or permanent ventricular pacing. Furthermore, recent data indi-
cated that upgrade procedures to biventricular pacing are asso-
ciated with a relatively high complication rate,6 suggesting that
more conclusive data are required before a general recommenda-
tion for an upgrade to a CRT system can be made.
Study design
Study objectives
The aim of the BUDAPEST-CRT Upgrade Study is to investigate the
safety and efficacy of upgrading to CRT from existing previously im-
planted PM or defibrillators, during a 12-month follow-up time in
patients with reduced ejection fraction (LVEF ≤ 35%), symptomatic
heart failure (NYHA II– IVa), and intermittent or permanent right
ventricular (RV) pacing (≥20%, with paced QRS complex ≥150 ms),
compared with therapy with ICD only.
The primary endpoint of the study is the composite of clinical and
echocardiographic parameters including the first occurrence of
a non-fatal HF event, or all-cause mortality, or less than 15% re-
duction in LVESV from baseline to 12 months, determined by
echocardiography.
Secondary endpoints are all-cause mortality, the composite end-
point of death or HF events, and changes in left ventricular ejection
fraction (LVEF) and left ventricular end-diastolic volume from base-
line to 12 months.
Tertiary endpoints are safety endpoints related to procedure suc-
cess as well as changes in functional (NYHA) class, biomarker para-
meters (NT-pro-BNP) after 1 year, quality of life, and 6 min walk test.
Study design
This is a prospective, international, multicentre, randomized con-
trolled clinical trial conducted in 30 European and Israeli investiga-
tional centres. The study will be conducted in accordance with the
Helsinki Declaration, the good clinical practice, and the applicable
regulatory requirements.7 All patients will provide their written in-
formed consent prior to enrolment (Figure 1).
Patient population
Patients with chronic cardiomyopathy (regardless of aetiology), re-
duced LVEF (≤35%), and symptomatic HF (NYHA functional
classes II– IVa) despite optimized medical treatment, who have a
single- or dual-chamber PM or ICD implanted at least 6 months be-
fore enrolment (with ≥20% RV pacing in the time period of ≥90
days prior to enrolment, paced QRS duration ≥150 ms).
The intrinsic rhythm is required to assess at enrolment in order to
exclude patients with typical Left Bundle Branch Block (LBBB)
morphology. Patients with atrial fibrillation/flutter or atrial tachycar-
dia can also be enrolled. The rate or frequency control management
What’s new?
† Cardiac resynchronization therapy upgrade from a conven-
tional pacemaker (PM) or implantable cardioverter defibrilla-
tor (ICD) takes a relatively high part of interventions. The
patient selection and the optimal time of the procedures
with measuring the risk–benefit ratio are according to the
physician’s discretion.
† While the current European Society of Cardiology guideline
does not contain conclusive data (with more multicentre,
randomized trials) on the superiority of cardiac resynchroni-
zation therapy with defibrillator (CRT-D) over ICD in pa-
tients with previously implanted PM or ICD devices with
reduced left ventricular (LV) function and symptomatic heart
failure (HF) who require intermittent or permanent ventricu-
lar pacing.
† The results of our prospective, randomized, multicentre clin-
ical trial will provide important information on the role of
CRT-D upgrade in patients with symptomatic HF (NYHA
II – IVa), reduced LV ejection fraction (≤35%), and wide-
paced QRS (≥150 ms) with intermittent or permanent right
ventricular pacing (≥20%).
Screening
1. Inclusion criteria met
2. No exclusion criteria present
Sign informed consent
Baseline visit
Randomization 3:2
CRT-D arm
Perform
device
upgrade (see
Table 2)
Perform
device
upgrade or
continue to
use current
ICD (see
Table 2)
1-Month follow-up
1- and 6-month visits
1. History/exam
2. Device interrogation
3. Assess adverse events
4. Assess endpoints
6-Month follow-up
12-Month, final follow-up
ICD arm
Yes
Yes
No
Patient ineligible
for the study
No
Final vist, 12 months
1. History/exam
2. ECG
3. Device interrogation
4. TTE
5. Lab tests
6. 6MWT
7. Assess adverse events
8. Assess endpoints
1. History/exam
2. ECG
3. Device interrogation
4. TTE
5. Lab tests
6. 6MWT
Baseline visit
Figure 1 Study flowchart.
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is based on the physician’s discretion before the enrolment and dur-
ing the follow-up.
Detailed inclusion and exclusion criteria are listed in Table 1.
Patient enrolment and randomization
After signing the written informed consent, eligible patients will
undergo a baseline evaluation including clinical history, physical
examination, assessment of NYHA class, 12-lead ECG with paced
and non-paced QRS complexes using VVI 40 bpm settings, echocar-
diography, device interrogation for assessment of RV pacing per-
centage, assessment of quality of life, 6 min walk test, and optional
blood test for assessment of NT-pro-BNP (Figure 1).
Subjects meeting all inclusion criteria, without having any of the
exclusion criteria, will be randomized to the CRT-D group (upgrade
of the existing device into CRT-D) or the ICD group (either contin-
ued ICD therapy in patients currently implanted with an ICD or up-
grade to an ICD from an existing PM).
Among patients randomized to the control group who require ICD
implantation, it is possible to implant a CRT-D device with or without
the LV lead implanted at the same time, but LV pacing has to be turned
off and the device has to be programmed to VVI/DDD ICD. The de-
cision of implanting a CRT-D device with the LV lead deactivated for
the ICD arm is left to the discretion of the principal investigator at each
site and will be recorded in the electronic CRF system. The random-
ization will be performed in a 3:2 ratio (CRT-D:ICD).
A total of 360 patients will be enrolled in the study.
Trial intervention
Device upgrades will be performed within 14 business days from
randomization. Patients assigned to the CRT-D group and those
with a PM, assigned to the ICD group, will undergo the device up-
grade procedure (Table 2). Patient with an existing ICD, assigned to
the ICD group, may not need a procedure unless a generator re-
placement, system revision, or upgrade to a dual-chamber system
is indicated by the enrolling physician. Decisions about lead
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Inclusion and exclusion criteria in the study
Inclusion criteria Exclusion criteria
(1) Age: over 18 years
(2) Cardiomyopathy with LVEF ≤ 35%, ischaemic or non-ischaemic
(3) Single- or dual-chamber PM or ICD implanted ≥6 months prior to
enrolment (battery depletion or another indication for upgrade is
not required)
(4) RV pacing ≥20% in the prior ≥90 days (use of algorithms to avoid
ventricular pacing is recommended, per discretion of the clinician)
(5) Paced QRS duration ≥ 150 ms
(6) Symptomatic HF with NYHA functional classes II– IVa ≥3 months
prior to enrolment, despite optimized medical therapy
(7) Informed consent
(1) CABG or PCI ≤ 3 months ago or planned
(2) AMI ≤ 3 months ago
(3) Unstable angina
(4) Planned cardiac transplant
(5) Acute myocarditis
(6) Infiltrative cardiomyopathy
(7) Hypertrophic cardiomyopathy
(8) Severe primary mitral, aortic, or tricuspid valve stenosis or insufficiency
(9) Tricuspid valve prosthesis
(10) Severe RV dysfunction (RV basal diameter . 50 mm)
(11) Chronic severe renal dysfunction (creatinine . 200 mmol/L)
(12) Pregnant women of planned pregnancy
(13) Subjects who are unable or unwilling to cooperate with the study
protocol
(14) Any comorbidity that is likely to interfere with the conduct of the study
(15) Participation in another trial
(16) Patients geographically not stable or unavailable for follow-up
(17) Intrinsic QRS with typical LBBB morphology
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Study interventions
CRT-D group ICD group
1. Existing PM
Addition of RV defibrillator lead
Addition of RA pacing lead (unless already has one or has permanent AF)
Addition of LV pacing lead
Extraction of old RV PM lead optional (physician’s judgement)
Any revision of the old lead(s) and device pocket, as necessary
Generator change to CRT-D
2. Existing ICD
Addition of RA pacing lead (unless already has one or has permanent AF)
Addition of LV pacing lead
Any revision of the old lead(s) and device pocket, as necessary
Generator change to CRT-D
1. Existing PM
Addition of RV defibrillator lead
Addition of RA pacing lead optional (physician’s judgement, unless
already has one or has permanent AF)
Extraction of old RV PM lead optional (physician’s judgement)
Any revision of the old lead(s) and device pocket, as necessary
Generator change to VVI or DDD ICD,
2. Existing ICD
Continue with existing device
Addition of RA pacing lead and upgrading to a DDD ICD is
optional (physician’s judgement, unless already has one or has
permanent AF)
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extraction are left to the individual judgement of each physicians
based on the actual recommendations.8
Use of Boston Scientific Corporation (Marlborough, MA, USA)
ICDs or CRT-D is encouraged in the study; however, it is left to
the physician’s discretion to even use device manufactured by other
companies. All devices implanted in the study have a CE certificate
and will be implanted according to their instruction for use and cur-
rent guidelines.9 In the ICD arm, choosing single- or dual-chamber
device is left to the physician’s decision. In the CRT-D arm, the LV
lead is recommended to be implanted in the lateral or postero-
lateral side branch of the coronary sinus. Transvenous implantation
is strongly preferred; however, alternative methods are also ac-
cepted if the transvenous attempt fails.
Follow-up
Patients will be followed up for 12 months after randomization
(Figure 1). The estimated duration of enrolment period is 36months,
which may be extended depending on the recruitment rate.
Regular, in-office follow-ups will be performed at 1, 6, and 12
months. Clinical parameters, ECG, device, echocardiographic, and
biochemical parameters will be collected at each follow-up visit
and stored in a central electronic database (Table 3).
Echocardiography assessment
After enrolment, a detailed echocardiographic report will be sub-
mitted to the Echocardiography Core Laboratory for central assess-
ment (Semmelweis University, Heart and Vascular Center,
Budapest, Hungary). Left ventricular volumes and ejection fraction
will be calculated using the biplane Simpson method. Echocardio-
graphic images will be obtained at baseline visit (after randomization
and before implantation) and at the 12-month follow-up visit. A de-
tailed echocardiographic protocol has been prepared and will be
sent to the enrolling centres for standard acquisition of the echocar-
diographic images. All sonographers in the study will be certified by
the Echocardiography Core Laboratory according to the inter-
national standards.
Device interrogation and programming
Lead impedance, sensing, and pacing parameters will be determined
for each lead. Device settings, Holter recording data including RV
pacing percentage, and all available tachyarrhythmia episodes with
EGMs will be interrogated. All retrieved data will be printed, saved
to a disk or a USB, and uploaded to a digital archive maintained by
the Coordination and Data Centre.
A DDD(R) or VVI(R) mode is required with base rate setting be-
tween 40 and 70 bpm. Atrio-ventricular (AV) delay should be pro-
grammed in DDD(R) devices to minimize RV pacing by using
SMART AV delay10 or echocardiographic optimization or fixed va-
lues (sensed AV delay 120–140 ms/paced AV delay 140–160 ms).
Recommended tachycardia therapy settings are as follows: VT
zone between 170 and 200 bpm monitor zone without therapy,
or VT therapy in case of secondary prevention with a duration delay
of 2.5 s. Ventricular fibrillation (VF) zone is over 200 bpm with a
2.5 s delay, ATP during charging (8 pulses at 88% of the tachycardia
cycle length) and subsequent shocks (first shock DFT + 10 or 30 J,
subsequent shocks should be maximum energy shocks).
Assessment of endpoints
Ascertainment of the endpoints of death and HF events will be per-
formed by the site investigators. The assessment of HF events are
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Study procedures
Visit/evaluation Patient
enrolment visit
Day 0
Device implantation
and programming
Within 14 days
1 month
FU visit
Day 30
6 months
FU visit
Day 180
12 months
FU visit
Day 365
Inclusion criteria x
Exclusion criteria x
Signed informed consent x
Clinical history x x x x
Physical examination x x x x
Assessment of NYHA class x x x x
12-Lead ECG (paced) x x
12-Lead ECG (at VVI 40 bpm) x x
Echocardiography x x
Device interrogation (print, save, upload) x x x x
Blood test (NP-pro-BNP) x1 x1
6 Min walk test x2 x
Randomization x
Assessment of clinical endpoints x3 x3 x3
Assessment of post-implantation complications x
SAE, AE, UADE, USADE x x x x x
Quality-of-life assessment using EQ-5D x2 x
1, Optional; 2, after the randomization but before implantation; 3, clinical endpoints; SAE, serious adverse event; AE, adverse event; UADE, unanticipated adverse device effect;
USADE, unanticipated serious adverse device effect.
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based on the physicians’ discretion. Clinical signs and symptoms are
required that are responsive to intravenous decongestive therapy or
an augmented decongestive regimen with oral or parenteral medi-
cations during hospitalization.
Death should be reported immediately. An independent HF and
Death committee blinded to treatment group or clinical characteristics
of the patients will review HF and death events. An event will be clas-
sified as a HF event (i) if the patient had symptoms and/or signs con-
sistent with congestive HF and (ii) received intravenous diuretic and/or
positive inotropic therapy for longer than 2 h or (iii) received an aug-
mented oral or intravenous HF therapy during an in-hospital stay due
to worsening of HF. An independent, blinded Arrhythmia Adjudication
Committee will review atrial and ventricular arrhythmia episodes.
Safety plan/study termination
A Data Safety Monitoring Board (DSMB) will perform pre-specified
scheduled interim safety analysis following the enrolment of 30 and
60% of study population. The statistical design will permit early ter-
mination of the trial if CRT efficacy is meaningfully greater than that
hypothesized for ICD only, or ICD-only efficacy is meaningfully
greater than that hypothesized for CRT. The study will be termi-
nated if the DSMB identifies a significant harm with an implanted
CRT-D over an ICD during the interim safety analysis.
Statistical analysis
The main objective of this study is to demonstrate a reduction in the
primary composite clinical and echocardiographic endpoint after
CRT upgrade (superiority of CRT-D upgrade vs. ICD only). Ana-
lyses will be performed (i) on an intention-to-treat basis (without
regard to device actually implanted/revised) and (ii) on efficacy basis,
censoring follow-up when a patient crosses over to a different de-
vice. The primary analyses will be stratified by the percentage of
baseline RV pacing as pre-specified in the study.
Sample size and statistical methods
A total of 360 patients will be enrolled and randomized to CRT-D
vs. ICD in a 3:2 ratio. The null hypothesis for the primary endpoint is
that the hazard rate, which is assumed to be constant across all study
intervals, is identical in the two groups (CRT-D v. ICD). The hypoth-
esis will be tested in a study in which subjects are entered and fol-
lowed up until (i) the primary composite endpoint occurs, (ii) the
patient drops out of the study, or (iii) the study ends while the pa-
tient is still being followed, in which case the patient is censored. All
subjects will be followed up for 12 months.
Power was calculated a priori based on a hazard ratio of 0.7 and a
primary composite endpoint event rate of 80% in the ICD group
over 12 months. The power calculation was based on higher RV pa-
cing rates, while no data is available ,40%. Although the risk seems
to correlate with RV pacing, the exact correlation is unclear. The at-
trition (dropout) rate was assumed at 0.01/interval. An instantan-
eous hazard rate of 0.134 for the ICD group and 0.094 for the
CRT-D group was assumed—this equals to a median survival time
of 5.17 intervals in the ICD group and 7.38 intervals in the CRT-D
group, a cumulative event-free survival at 12 intervals of 0.2 for the
ICD group and 0.32 for the CRT-D group. The two-tailed alpha was
set at 0.05. A total of 144 patients will be entered into the ICD group
and 216 into the CRT-D group to achieve a power of 80.1% to yield
a statistically significant result.
Discussion
Several guidelines have been published on optimal patient selection
for CRT implantation; however, recommendations on CRT upgrades
are still ambiguous without any details for the different causes for
chronic RV pacing (Table 4). The 2013 European Society of Cardi-
ology (ESC)/European Heart Rhythm Association (EHRA) guidelines
recommend CRT upgrade in patients with LVEF, 35%, NYHA III
and IVa, and high percentage of ventricular pacing—although the cited
evidence stands for de novoCRT implantations and crossover trials as
opposed to upgrades from existing devices, with level of evidence ‘B’
and class I indication.9 The 2012 ACCF/AHA/HRS guidelines are list-
ing CRT upgrade with IIa indication, level of evidence ‘C’ for patients
with LVEF ≤ 35%, and a need for at least 40% ventricular pacing, for
both new implants and device replacements.11 The 2012 ESC/HFA
Table 4 Indication for upgrade to CRT in patients with existing PM or ICD
ESC/EHRA 20139 CRT is indicated in HF patients with LVEF, 35% and high percentage of ventricular
pacing who remain in NYHA class III and ambulatory IV despite adequate medical
treatment.
Remark: Patients should generally not be implanted during admission for acute
decompensated HF. In such patients, guideline-indicated medical treatment
should be optimized and the patient reviewed as an out-patient after stabilization.
It is recognized that this may not always be possible.
Class I
LOE B
ACCF/AHA/HRS 201211 CRT can be useful for patients on GDMTwho have LVEF ≤ 35% and are undergoing
new or replacement device placement with anticipated requirement for
significant (.40%) ventricular pacing.
Class IIa
LOE C
ESC/HFA 201212 CRT is recommended as an alternative to conventional RV pacing in patients with
HF-REF who have a standard indication for pacing or who require a generator
change or revision of a conventional PM.
No specific recommendations
for CRT upgrade
ESC/EHRA, European Society of Cardiology/European Heart Rhythm Association; GDMT, Guideline determined medical therapy; ACCF/AHA/HRS, American College of
Cardiology Foundation/American Heart Association/Heart Rhythm Society; ESC/HFA, European Society of Cardiology/Heart Failure Association.
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guidelines,12 the 2013 Appropriate Use Criteria document, endorsed
by the ACCF/HRS/AHA,13 and the most recent 2015 ESC/EHRA
guideline on ventricular arrhythmias and sudden cardiac death do
not provide any recommendations on CRT upgrade.14
Effects of chronic right ventricular pacing
Large randomized trials have shown that chronic RV pacing is asso-
ciated with an increased risk of HF, atrial fibrillation, and mortality.9,15
The Dual-Chamber and VVI Implantable Defibrillator (DAVID) trial
demonstrated worse outcomes in patients with reduced LVEF and
dual-chamber ICD programming to DDDR 70 bpm when compared
with patients with VVI 40 bpm pacing. Every 10% increase in RV pa-
cing increased the risk of death or HF hospitalization by 16%. The
most significant separation was observed with 40% RV pacing, strong-
ly predicting death or HF hospitalization (HR ¼ 5.2, P ¼ 0.008).16
Another multicentre, randomized clinical trial, the Mode Selec-
tion Trial, confirmed the correlation of RV pacing and impaired clin-
ical outcome in patients with preserved LVEF and sinus node
dysfunction. The risk of HF hospitalization linearly increased with
RV pacing up to 40%.15
In contrast, Olshansky et al. suggested that reducing RV pacing
does not necessarily eliminate the risk of an adverse outcome. In
the INTRINSIC RV study, patients were categorized into six groups
based on increasing RV pacing rates. A significant difference was
found between rates concerning patients’ age, history of ventricular
tachycardia, atrial fibrillation, atrial flutter, and amiodarone therapy.
Adjusting for these parameters, the best outcome was seen
in patients with RV pacing between 10 and 19% (2.8% event
rate over a median follow-up of 11.6 months). Increasing RV
pacing has been found predictive of death or HF hospitalization
(P ¼ 0.003). Other than expected, patients with rare RV pacing
(0–9%) experienced worse outcome (8.1% event rate, P ¼ 0.016),
although a lower RV pacing rate may be advantageous to improve
AV dyssynchrony.17
Possible benefits and limitations of cardiac
resynchronization therapy in patients with
heart failure and intermittent pacing
Small crossover trials have compared RV pacing only to CRT in
patients with symptomatic bradycardia and reduced LVEF. They
showed that CRT reduced mortality, HF hospitalization, and
lead to reverse ventricular remodelling.9,18 For the first time,
the Biventricular vs. Right Ventricular Pacing in Heart Failure Pa-
tients with Atrioventricular Block Trial (BLOCK HF) showed that
CRT is superior to RV pacing in patients with AV block, LVEF ≤
50%, and HF class NYHA I– III. After a median follow-up of 37
months, primary endpoints (time to death from any cause, HF visit
that required intravenous therapy, or ≥15% increase in LVESV in-
dex) occurred in 190 of 342 patients (55.6%) in the RV pacing
group, compared with 160 of 349 (45.8%) in the CRT group
(HR ¼ 0.6–0.9, posterior probability of HR ,1 ¼ 0.9978). The
LV lead-related complications occurred in 6.4% of patients in
the CRT-treated group.9
The Homburg Biventricular Pacing Evaluation trial compared
CRT with RV pacing in patients with bradycardia and LV dysfunction
(LV end-diastolic diameter ≥60 mm and LVEF ≤ 40%). Three
months of RV pacing vs. biventricular pacing were studied in 30 pa-
tients. Improved echocardiographic parameters, laboratory values,
and quality of life scores, as well as improved peak exercise capacity,
were found only with biventricular pacing.9
The Conventional vs. Multisite Pacing for BradyArrhythmia Ther-
apy (COMBAT) crossover study compared CRT vs. RV pacing in 60
patients with AV block, LVEF, 40%, andHFwithNYHA classes II–IV.
After a follow-up of 17.5 months, the quality of life, NYHA class, and
echocardiographic parameters improved in patients withCRT.Overall
mortality was significantly higher in patients with RV pacing alone
(86.7% vs. 13.3%, P ¼ 0.012).18 Studies performed in patients with
preserved LVEF also demonstrated benefit with CRT, showing
increased reverse LV remodelling.9
The Long term from the Pacing to Avoid Cardiac Enlargement
trial investigated the clinical outcomes of 149 patients with CRT,
randomized to 1 year of RV or biventricular pacing after an ex-
tended follow-up of 5 years (mean 4.8+1.5 years). In the RV pacing
group, LVEF and LVESV worsened progressively during 1-year,
2-year, and long-term follow-ups, whereas both parameters re-
mained unchanged in the CRT group (LVEF difference, respectively,
P, 0.001). However, patients with RV pacing needed significantly
more HF hospitalization (23.9%) than CRT patients (14.6%).19 In
summary, chronic biventricular pacing seems to be superior to
RV-only pacing, but the results cannot be extrapolated to patients
with intermittent or chronic pacing who developed worsening of
HF only recently.
The RD-CHF study upgraded 56 patients from VVI pacing
(NYHA III and IV, and LV dyssynchrony) to CRT at the time of gen-
erator replacement. The study had a 3-month crossover design with
RV pacing only or CRT. Cardiac resynchronization therapy pacing
significantly improved NYHA class, 6MWT, and quality of life.9
In the Resynchronization–Defibrillation for Ambulatory Heart
Failure Trial (RAFT) study, 644 of 1346 enrolled (48%) patients
underwent de novo CRT implantation, 80 patients were upgraded
to CRT from a previously implanted ICD device, and 60 patients
underwent CRT upgrade 6 months after the end of the initial study.
The success rate was 95.2% for de novo, 96.3% for upgrade, and
90.0% for post-trial CRT upgrade sub-study (P ¼ 0.402). The acute
complication rate was 26.2% for de novo, 18.8% for upgrade, and
3.4% for the sub-study CRT upgrade (P, 0.001), most commonly
due to LV lead dislodgement. The main reasons for not attempting
upgrade in the sub-study group were patient preference (31.9%),
NYHA class I (17.0%), and QRS , 150 ms (13.1%). The authors
conclude that the success of CRT upgrade is high and that the com-
plication rates are similar to de novo CRT implantation.20 However,
in the prospective REPLACE Registry with 1750 patients undergoing
device replacement, those who required upgrade experienced a
high rate of major complications during a 6-month follow-up time
(18% vs. only 4%).
There is still limited information concerning the efficacy and
safety of CRT upgrade among patients with LV dysfunction and
intermittent RV pacing, particularly in patients with moderate symp-
toms with lower percentage of RV pacing, or with a narrow QRS
(,150 ms). Patients who receive CRT-D upgrade may experience
additional benefits, but this needs to be proved in a prospective
study. Therefore, we have designed the BUDAPEST-CRT Upgrade
Study.
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Conclusion
The BUDAPEST-CRT Upgrade Study will evaluate the efficacy and
safety of CRT-D upgrade when compared with ICD therapy in pa-
tients with previously implanted PM or ICD devices, reduced
LVEF ≤ 35%, symptomatic heart failure (NYHA II– IVa), and inter-
mittent or permanent RV pacing with wide-paced QRS ≥ 150 ms.
Our study results will provide conclusive data on the effects of
CRT-D upgrade procedure in this patient population and confirm
the indication of CRT-D upgrade.
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